San Diego State University Research Finds Compensation Changes may be Necessary for Local Life Sciences Industry

SAN DIEGO–(Business Wire)–
The College of Business Administration at San Diego State University (SDSU)
announced today that research findings of SDSU management professors indicated
the current business model for most San Diego life sciences companies is not
sustainable and models with more employee ownership may have a positive effect
on these organizations. The research was published in the current issue of
Compensation & Benefits Review.

Drs. Gangaram Singh and Lynn Shore, both management professors at SDSU`s College
of Business Administration built on previous research which indicated that 70
percent of executives from venture capital-funded biotech organizations say
“that the current business [model] is not a viable business option for the
future.” Over 100 top executives of the local life sciences industry were
surveyed on the usage of company ownership through stock distribution,
profit/gain sharing and 401 (k). Singh and Shore concluded that employee
ownership opportunities were predominantly used to attract, motivate and retain
talented employees. Ownership options such as employee stock ownership plans and
investment in company stocks as part of the 401 (k) plan were less commonly
used.

“When employees make the choice to invest their financial resources in the
company, then the process of building an alternative model will take a
foothold,” reported Shore and Singh. “Otherwise employee ownership in its
current form will serve as a transactional mechanism to hire, retain and
motivate employees until an exit strategy is executed, such as partnering with a
big pharmaceutical company. Employee ownership, in short, can provide a vehicle
to effectuate the change in the business model, which is important for the
long-term viability of the life sciences industry.”

“The biosciences industry is critical to San Diego, both in terms of their
life-saving science and their impact on the local economy,” said Mary Ann
Beyster, president of the Foundation for Enterprise Development, who funded the
research. “It is imperative that the industry adopt a business model that
attracts and retains talent in order to continue to meet both their scientific
and business objectives. It is this research that can provide executives with
some of the pieces to the puzzle in how to make that a reality.”

The Foundation for Enterprise Development was established by Dr. J.R. Beyster,
founder of Scientific Applications International Corporation (SAIC) for the
purpose of promoting business principles and practices that encourage free
enterprise and advance science and technology innovations with impact on
nationally important interests.

About the College of Business Administration

With over 5,000 students, SDSU`s College of Business Administration is one of
the largest business schools in the U.S. Its programs have been ranked among the
top programs in the country by U.S. News & World Report and the Princeton
Review. For more information, visit www.sdsu.edu/business.

About SDSU

San Diego State University is the oldest and largest higher education
institution in the San Diego region. Since it was founded in 1897, the
university has grown to offer bachelor`s degrees in 84 areas, master`s degrees
in 76 areas and doctorates in 16 areas. SDSU`s more than 30,000 students
participate in academic curriculum distinguished by direct contact with faculty
and an increasing international emphasis that prepares them for a global future.
For more information, visit www.sdsu.edu.

SDSU College of Business Administration
Suzanne Finch
Chief Communications Officer
(619) 594-0206
sfinch@mail.sdsu.edu

Copyright Business Wire 2010

U.S. Federal Trade Commission and the Courts Prohibit Creation or Delivery of Checks Without Identity Verification through G7

Leading Marketer and Manufacturer of Check Creation Solutions Appointed to
Implement Verification Procedures Nationwide Associated with Check Creation or
Delivery
SAN DIEGO–(Business Wire)–
G7 Productivity Systems (“G7″) announces that the Federal Trade Commission
(“FTC”) and the Courts have taken affirmative steps to restrict the ability of
consumers and businesses to create or deliver “unverified” checks. G7, a leading
marketer of check printing and delivery solutions, has been a co-defendant in a
precedent setting case before the United States District Court in San Diego that
resulted in a Final Order (“Final Order”) which is hereby published. The Final
Order was recently affirmed by a panel of the Ninth Circuit Court of Appeals and
appoints G7 to implement new verification procedures associated with the
creation or delivery of checks. The FTC contends that any creation or delivery
of checks for existing and prospective customers is prohibited under the Final
Order unless G7 has first performed authentication of the customer`s identity
and the customer`s control over any bank account used in connection with the
check creation or delivery.

The provisions of the Final Order provide that Industry partners, participants
and publishers who are involved in the “creation” or “delivery” of a check for
an existing or prospective customer may be permanently restrained and enjoined
from allowing the creation or delivery of any checks unless the prospective
customer`s identity and account control have been verified through G7.

Please visit www.G7PS.com to learn about the class of goods and services that
may be affected. We kindly request that anyone participating in the creation or
delivery of checks contact G7 to coordinate compliance with the Final Order.

About G7

G7 Productivity Systems, Inc., based in San Diego, CA, is a leading publisher
and manufacturer of productivity software and supplies for both home and
business use. G7′s products are available in over 4,000 retail outlets in the US
and Canada.

G7 creates business automation solutions that enhance productivity while
reducing costs. Currently, G7 offers products and services in many important
areas of business enhancement, including check creation software and printers,
magnetic (MICR) and non-magnetic ink and toner, blank and preprinted check
paper, forms creation tools, data capture solutions, customer relationship
management software, as well as solutions to enhance sales automation, human
resources, accounting, and e-commerce efficiency.

G7 Productivity Systems
James Danforth, EVP/CFO
858-675-1095 x202
jdanforth@g7ps.com

Copyright Business Wire 2010

Robbins Umeda LLP Announces Investigation of Innospec Inc.

SAN DIEGO–(Business Wire)–
Robbins Umeda LLP has commenced an investigation into possible breaches of
fiduciary duty and other violations of the law by certain officers and directors
at Innospec Inc. (“Innospec” or the “Company”) (NASDAQ:IOSP). Innospec engages
in the development, manufacture, blending, and marketing of fuel additives and
other specialty chemicals to oil refineries and other chemical and industrial
companies worldwide. The Company was formerly known as Octel Corp. and changed
its name to Innospec in January 2006. Innospec was founded in 1938 and is
headquartered in Newark, Delaware.

Robbins Umeda LLP’s investigation concerns whether Innospec’s directors and
officers breached their fiduciary duties by causing or allowing the Company to
violate the Foreign Corrupt Practices Act (“FCPA”).

On March 18, 2010, Innospec pled guilty to bribing Iraqi and Indonesian
officials in violation of the FCPA and agreed to pay a $40.2 million fine to the
governments of the United States and the United Kingdom. Additionally, in a
recent filing with the U.S. Securities and Exchange Commission, Innospec
disclosed legal costs related to their guilty plea to be more than $35 million
and an accrual of $3.9 million spent in the first quarter of 2010 in “respect of
probable future compliance monitor expenses.”

If you are a shareholder of Innospec, plan to continue to hold your shares, and
would like more information about your rights as a shareholder, please contact
attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at
info@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm, which has significant
experience representing investors in shareholder derivative actions, securities
fraud class actions, and merger-related shareholder class actions. For more
information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

Robbins Umeda LLP
Gregory E. Del Gaizo, 800-350-6003
info@robbinsumeda.com

Copyright Business Wire 2010

Robbins Umeda LLP Announces Investigation of Avon Products Inc.

SAN DIEGO–(Business Wire)–
Robbins Umeda LLP has commenced an investigation into possible breaches of
fiduciary duty and other violations of the law by certain officers and directors
at Avon Products Inc. (“Avon” or the “Company”) (NYSE: AVP). Avon manufactures
and markets beauty and related products worldwide. The Company markets its
products through direct selling and independent representatives, as well as
through distributorships. Avon was founded in 1886 and is headquartered in New
York, New York.

Robbins Umeda LLP’s investigation concerns whether Avon’s directors and officers
breached their fiduciary duties in connection with the Company’s potential
violations of the Foreign Corrupt Practices Act (“FCPA”).

Avon first announced that it was investigating possible violations of the FCPA
in 2008. The Company recently announced that its expenses for its internal FCPA
investigation have increased enough to impact results. In particular, Avon
disclosed that it incurred “significant professional fees associated with the
Company’s internal investigation resulting from an allegation of FCPA violations
in China.” In April 2010, the Company suspended four employees pending its
internal bribery investigation, and put three executives in China and another in
New York on administrative leave. The investigation has now expanded to at least
four international business units outside of China.

If you are a shareholder of Avon, plan to continue to hold your shares, and
would like more information about your rights as a shareholder, please contact
attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at
info@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm, which has significant
experience representing investors in shareholder derivative actions, securities
fraud class actions, and merger-related shareholder class actions. For more
information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

Robbins Umeda LLP
Gregory E. Del Gaizo, 800-350-6003
info@robbinsumeda.com

Copyright Business Wire 2010

Illumina Announces First Customer Shipments of Omni2.5 BeadChip

Array Provides Up to 50% More Coverage of Human Genome Variation
SAN DIEGO–(Business Wire)–
Illumina, Inc. (NASDAQ:ILMN) today announced that it has begun shipping its new
HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains
millions of newly discovered genome-wide common and rare variants from the 1,000
Genomes Project (1kGP), selected to maximize its ability to detect new
associations. Omni2.5 represents a significant milestone in Illumina`s 2010
genome-wide association studies (GWAS) roadmap, announced in late 2009, that is
providing access to superior common and rare variant content as it is deployed
from the 1kGP. Omni2.5 delivers unprecedented genome coverage for both SNP and
copy number variation (CNV) analysis, while retaining the industry leading data
quality and simple workflow that has made Infinium arrays the gold standard GWAS
analysis tool.

“The vast amount of data now emerging from bold resequencing efforts exemplified
by the international 1000 Genomes Project, together with informed SNP selection
by a world-leading group of researchers, now enables next-generation GWAS,” said
David Bentley, Ph.D., vice president and chief scientist at Illumina. “We`ve
reached a pivotal time in genetics when many millions of new variants are
becoming available as the result of next-gen sequencing. For the first time,
investigators are able to use a greatly expanded spectrum of novel variants to
search for the missing heritability in common, complex diseases, using high
capacity genotyping to screen very large sample collections quickly, thoroughly
and cost-effectively. We now can harness the power to discover SNPs by
large-scale sequencing with the Omni2.5 genotyping array.”

Omni2.5 is delivered in a high-throughput 4-sample format for a total of
approximately 10 million markers per array, providing immediate utility for the
next-generation of GWAS. It is compatible with an iScan or HiScan System. In
addition, the company is now shipping:

* The HumanOmni1S-8 BeadChip,which provides a simple upgrade path for current or
former users of Illumina`s Omni1-Quad or OmniExpress BeadChips, enabling
researchers to easily access new 1kGP content without having to purchase the
Omni2.5. Aggressively priced, this new 8-sample array contains the majority of
new content present on the Omni2.5 and allows for processing of nearly 1,000
samples per week.
* A new sample preparation workflow that allows researchers to save time and
money while taking advantage of the 2010 GWAS roadmap.This new
workflowallowsresearchers to prepare their DNA samples once and process them
across multiple arrays in the Omni family, such as the Omni1 or OmniExpress and
Omni1S, or the Omni2.5 and, later this year, the Omni2.5S.

As with all other Infinium HD products, the Omni1S and Omni2.5BeadChips support
CNV analyses for disease-association studies and are fully compatible with
Illumina’s automation solutions for processing hundreds to thousands of samples
on a weekly basis. For more information about Illumina`s whole-genome genotyping
products, please visit http://www.illumina.com/gwas.

About Illumina

Illumina (www.illumina.com) is the leading developer, manufacturer, and marketer
of life-science tools and integrated systems for the analysis of genetic
variation and biological function. Using our proprietary technologies, we
provide a comprehensive line of products and services that currently serve the
sequencing, genotyping, and gene expression markets, and we expect to enter the
market for molecular diagnostics. Our customers include leading genomic research
centers, pharmaceutical companies, academic institutions, clinical research
organizations, and biotechnology companies. Our tools provide researchers around
the world with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract valuable
medical information from advances in genomics and proteomics. We believe this
information will enable researchers to correlate genetic variation and
biological function, which will enhance drug discovery and clinical research,
allow diseases to be detected earlier, and permit better choices of drugs for
individual patients.

Forward Looking Statements

This release contains forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements include challenges
inherent in new product development and manufacturing and the other factors that
are detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to update any
forward-looking statements after the date of this release.

Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Senior Manager, Public Relations
858-882-6822
wgrabill@illumina.com

Copyright Business Wire 2010

Life Settlement Awareness Month Begins Today

Event Opens with Record Number of Registrations
SAN DIEGO–(Business Wire)–
Celebrating five years of free life settlement industry education, Life
Settlement Solutions, Inc. (LSS) kicks off Life Settlement Awareness Month
(LSAM) events today.

LSAM is one of the industry`s largest educational efforts and has been held each
June since 2006. It is designed to bring timely industry education to financial
and insurance professionals, and qualified institutional participants of all
experience levels.

Registration for 2010 events opened in late-April 2010 and more professionals
have registered this year than in any previous year.

“To date we have provided education through LSAM to more than 10,000
professionals,” said Larry Simon, president and CEO, Life Settlement Solutions,
Inc. “Every year studies show that the main barrier to market entry is the lack
of education. It is our goal to break down this barrier by providing free
educational opportunities to the marketplace, thus advancing the industry
forward.

“Since the financial crisis began, we`ve seen an influx of new participants with
piqued interest in alterative assets, like life settlements. We`ve done a lot
with this year`s program to ensure we are catering to that demographic.”

All events are web-based and free to attend. The schedule is as follows:

* June 1 – Fundamentals of Life Settlements
* June 3 – Advanced Strategies and Case Studies
* June 8 – Qualified Participants Only Part 1 – Current Opportunities and State
of the Market
* June 16 – Broker Panel: Understanding Providers and Brokers
* June 22 – The Life Settlement Marketplace – Regulatory Climate; Market Trends
* June 24 – Qualified Participants Only Part 2 – Portfolios, Securitization,
Settlement Allocation impact on overall Portfolios

Space is limited and pre-registration is required. Events are open to financial
and insurance professionals, and qualified institutional participants of all
experience levels. To register, visit the events page of
www.lifesettlementawarenessmonth.com, or contact Angie Robert at
arobert@lifefirms.com.

This release and the webinars referenced herein are not and should not be
construed as a solicitation to buy or sell any securities, and Life Settlement
Solutions, Inc and its affiliates do not provide legal, accounting or tax
advice.

Life Settlement Solutions, Inc.
Angie Robert, 858-576-8067
arobert@lifefirms.com

Copyright Business Wire 2010

Illumina to Announce First Quarter 2010 Financial Results on Wednesday, April 28, 2010

SAN DIEGO–(Business Wire)–
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for
first quarter 2010 following the close of market on Wednesday, April 28, 2010.

On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time), Jay Flatley,
president and chief executive officer, and Christian Henry, senior vice
president, chief financial officer and general manager of Life Sciences, will
host a conference call with analysts, investors, and other interested parties to
discuss financial and operating results.

Conference Call Details:

The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on
Wednesday, April 28, 2010. Interested parties may listen to the call by dialing
866.578.5801 (passcode: 41726099), or if outside North America, by dialing
+617.213.8058 (passcode: 41726099). Individuals may access the live
teleconference under the “Corporate/Investor Information” tab of Illumina’s web
site at www.illumina.com.

A replay of the conference call will be available from 5:00pm Pacific Time
(8:00pm Eastern Time) on April 28, 2010, through May 5, 2010, by dialing
888.286.8010, or if outside North America, by dialing +1.617.801.6888 (passcode:
52772593).

About Illumina

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and
marketer of life-science tools and integrated systems for the large-scale
analysis of genetic variation and biological function. Using our proprietary
technologies, we provide a comprehensive line of products and services that
currently serve the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers include
leading genomic research centers, pharmaceutical companies, academic
institutions, clinical research organizations, and biotechnology companies. Our
tools provide researchers around the world with the performance, throughput,
cost effectiveness, and flexibility necessary to perform the billions of genetic
tests needed to extract valuable medical information from advances in genomics
and proteomics. We believe this information will enable researchers to correlate
genetic variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit better
choices of drugs for individual patients.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do not intend to
update any forward-looking statements after the date of this release.

Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Public Relations Manager
+858-882-6822
wgrabill@illumina.com

Copyright Business Wire 2010

audifon Adopts Sound Design Technologies` WOLVERINE DSP Platform in elia Hearing Systems

SAN DIEGO–(Business Wire)–
audifon, a global provider of innovative high-quality hearing systems and Sound
Design Technologies (SDT), a leading designer and manufacturer of ultra-low
power semiconductor solutions, algorithms and software infrastructure for
hearing instruments, today jointly announced that audifon has adopted SDT`s
WOLVERINE DSP platform in its brand new elia family of hearing systems.

“With elia we`ve developed a product that offers unparalleled sound experience
for our discerning customers. The numerous automated features in elia packaged
in attractive hearing aid styles offers significant leap in performance and
functionality, ensuring unsurpassed listening experience for every client”, says
Dr. Alexander Kind – President and CEO of audifon.

elia is the most advanced and the most intuitive audifon hearing system ever.
Superior automatic performance on elia is enhanced with a variety of hearing
instrument product styles fitting mild to severe hearing losses, delivering
incomparable listening is every situation. elia is available in trendy, almost
invisible form factors ranging from receiver-in-the-ear (RITE) to custom CICs in
a range of attractive colours.

“Our collaboration with audifon is another example of enabling innovation by
bringing leading-edge semiconductor processes and our miniaturized packaging
capability to our customers,” commented SDT`s President and CEO, Ian Roane.
“WOLVERINE offers to our customers, the best in class algorithm design
flexibility with power efficiency that has surpassed the performance of legacy
analog amplifiers as well as hardwired digital ASICs.”

WOLVERINE DSP, a finalist in EDN`s 20th annual innovation awards for best
multiprocessing system, is the hearing industry`s first 90nm monolithic DSP
system. Targeting the entire hearing aid market segment from basic digital to
premium adaptive digital signal processing with unrivalled bandwidth, current
efficiency and programming flexibility; WOLVERINE DSP delivers matchless
performance for hearing aid product designs. Introduced in April 2009, WOLVERINE
DSP is available in variety of form factors ranging from 3.8 mm X 2.8mm WLCSP
packages to 5.6 mm X 3.2 mm miniaturized hybrid assemblies. For more
information, visit http://www.sounddes.com/products_Wolverine.php.

About audifon hearing systems

audifon develops and produces modern and powerful hearing systems. Delivering
quality in design and production, audifon assures an excellent price-value ratio
and high customer satisfaction. audifon’s extensive range of hearing solutions
improves the quality of people`s lives in more than 65 countries worldwide. For
decades, audifon is one of the preferred hearing system brands. Trust in our
know-how and experience superior hearing system technologies now. For additional
information on audifon`s products and services, visit www.audifon.com.

About Sound Design Technologies

Sound Design Technologies Ltd., based in Burlington, Ontario, Canada, is a
leading designer and manufacturer of ultra-low power semiconductor solutions,
algorithms and software infrastructure for hearing instruments, portable battery
powered DSP applications, advanced high density interconnect technologies used
in custom miniaturized 3D Multi-Chip Modules (MCM), System-In-Package (SIP) and
Stacked Chip Scale Packages (S-CSP). Previously a division of Gennum
Corporation, SDT has a 37-year history of innovation in developing leading-edge
miniaturized audio processors. For more information on SDT products and
services, visit www.sounddesigntechnologies.com.

elia, audifon and audifon logoare trademarks or registered trademarks of audifon
GmbH & Co. KG.
Sound Design Technologies, Sound Design Technologies logo, WOLVERINE are
trademarks or registered trademarks of Sound Design Technologies Ltd.
All other trademarks and trade names are the property of their respective owners

Photos/Multimedia Gallery Available:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6248889〈=en

audifon Hearing Systems
audifon GMBH & Co. KG
+49-3635-4056-590
contact@audifon.com
or
audifon USA
+1-386-668-8812
contact.usa@audifon.com
or
Sound Design Technologies
Shailja Tewari, +1-905-635 0800
stewari@sounddes.com

Copyright Business Wire 2010

PURE Bioscience to Report Second Quarter 2010 Results on March 11

Conference Call to Begin at 4:30 p.m. Eastern
SAN DIEGO–(Business Wire)–
PURE Bioscience (NASDAQ:PURE) today announced that it will report results for
the second quarter of fiscal 2010 after market close on Thursday March 11, 2010.

Michael L. Krall, President and CEO, will host a conference call on Thursday ,
March 11, 2010 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to review and discuss
second quarter financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call
by dialing 877-407-8033 or (International) 201 689-8033 a few minutes before the
call start time.

The call is being webcast by Vcall and can be accessed at www.purebio.com.
Investors can also access the webcast at www.InvestorCalendar.com.

The webcast will be available for replay through June 12, 2010. A replay of the
conference call will be accessible until midnight June 11, 2010 by dialing
877-660-6853 or (International) 201-612-7415, and entering the Account #: 286
and the Conference ID #: 346416.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that
provide solutions to numerous global health challenges, including Staph (MRSA).
PURE’s proprietary high efficacy/low toxicity bioscience technologies, including
its silver dihydrogen citrate-based antimicrobials, represent innovative
advances in diverse markets and lead today’s global trend toward industry and
consumer use of “green” products while providing competitive advantages in
efficacy and safety. Patented SDC is an electrolytically generated source of
stabilized ionic silver which formulates well with other compounds. As a
platform technology, SDC is distinguished from competitors in the marketplace
because of its superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon, California (San
Diego metropolitan area). Additional information on PURE is available at
www.purebio.com.

PURE Investor Contact:
Lippert/Heilshorn & Associates
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
or
PURE Media Contact:
Gutenberg Communications
Michael Gallo
212-239-8594
mgallo@gutenbergpr.com

Copyright Business Wire 2010

Systech`s Newest Networking Solutions Featured at ETA

Dial-to-IP Gateways and Serial-to-IP Device Servers for Enabling IP
Communications
SAN DIEGO–(Business Wire)–
At the upcoming Electronic Transaction Association (ETA) show in Las Vegas,
Systech Computer Corporation will be exhibiting its entire line of IP enabling
solutions for electronic funds transaction applications.

Systech`s dial-to-IP converter gateways permit existing, dial-based payment
devices (e.g. ATMs, payment and gift card terminals, and other POS devices) to
simply and efficiently re-route transactions via the Internet or private IP
networks instead of dial up telephone lines, realizing the benefits of high
speed broadband communications. The dial-to-IP product line being featured at
the show includes Internet payment gateway, dial back-up and SSL security
models, as well as the company`s proven networking software products. At the
show, Systech will be previewing its newest software suite product, the ONDEMAND
Remote Access and Management system for remote location management and control
applications.

The ETA Annual Meeting and Expo provides professionals with insight into the
critical issues shaping the industry and how to leverage this knowledge to build
your business, increase sales, strengthen compliance, and protect customer data.
This premier event is the largest gathering of electronic payments professionals
and provides endless opportunities for building new relationships and connecting
with the experts.

This year`s ETA show is being held at the Mandalay Bay Convention Center in Las
Vegas, NV, April 20 through April 23, 2009. Systech`s booth at the show is #457.

Systech Computer Corporation is an industry leader in the design and manufacture
of distributed network conversion, access, gateway, server and switch products
for enabling IP communications in existing, non-IP based systems and networks.
Its innovative solutions are deployed in a broad range of worldwide markets
spanning electronic transaction, point of sale, convenience store, retail
operations, and industrial and commercial facility management applications. Over
350,000 Systech distributed networking products facilitate mission critical
applications worldwide. Additional information can be found at www.systech.com.

* Systech ONDEMAND software suite patent pending.

ONDEMAND Remote Access and Management is a trademark of Systech Computer
Corporation.

Systech Computer Corporation
Cheri Houchin
Director of Marketing Services
800-800-8970, x 429
cheri.houchin@systech.com

Copyright Business Wire 2009

Systech Launches Software Suite for Remote Device Management and Control Solutions

New ONDEMAND System Targets Distributed Automation Solutions
SAN DIEGO–(Business Wire)–
Systech Computer Corporation, a leading provider of IP network enabling
solutions, today announced its ONDEMAND Remote Access and Management System* for
remote device control applications. The new software product suite includes (1)
host server software and (2) remote device software that can be pre-configured
and installed on Systech`s network device server and IPG gateway products.
Systech`s NativeCOM port redirector software can be enabled to facilitate
application access to remote serial-based devices.

Managing and controlling distributed serial devices in application-specific
automation systems, such as home automation, HVAC, temperature and lighting
automation, home and plant physical security and air filtration systems, can
create costly and slow response service and support issues. According to Mark
Fowler,

Coughlin Stoia Geller Rudman and Robbins LLP Files Class Action Suit Against Coach, Inc.

SAN DIEGO–(Business Wire)–
Coughlin Stoia Geller Rudman and Robbins LLP (“Coughlin Stoia”)
(http://www.csgrr.com/cases/coach/) today announced that a class action has been
commenced in the United States District Court for the Southern District of New
York on behalf of purchasers of Coach, Inc. (“Coach”) (NYSE:COH) publicly traded
securities during the period between January 23, 2007 and October 22, 2007 (the
“Class Period”).

If you wish to serve as lead plaintiff, you must move the Court no later than 60
days from today. If you wish to discuss this action or have any questions
concerning this notice or your rights or interests, please contact plaintiff`s
counsel, Darren Robbins of Coughlin Stoia at 800-449-4900 or 619-231-1058, or
via e-mail at djr@csgrr.com. If you are a member of this class, you can view a
copy of the complaint as filed or join this class action online at
http://www.csgrr.com/cases/coach/. Any member of the putative class may move the
Court to serve as lead plaintiff through counsel of their choice, or may choose
to do nothing and remain an absent class member.

The complaint charges Coach and certain of its officers and directors with
violations of the Securities Exchange Act of 1934. Coach engages in the design
and marketing of accessories and gifts for men and women in the United States
and internationally.

The complaint alleges that during the Class Period, defendants reported strong
growth for the Company and forecast similar growth going forward. However,
defendants failed to disclose that the Company`s growth rate was, in fact,
unsustainable. Then, on October 23, 2007, before the market opened, Coach
announced that although its fiscal first-quarter profit rose 23%, traffic in its
U.S. retail stores was weak and the Company expected a slow-down in the coming
holiday season. As a result of this announcement, Coach`s stock price dropped
$4.87 per share (or 12%) to close at $36.60 per share on October 23, 2007.

Plaintiff seeks to recover damages on behalf of all purchasers of Coach publicly
traded securities during the Class Period (the “Class”). The plaintiff is
represented by Coughlin Stoia, which has expertise in prosecuting investor class
actions and extensive experience in actions involving financial fraud.

Coughlin Stoia, a 190-lawyer firm with offices in San Diego, San Francisco, Los
Angeles, New York, Boca Raton, Washington, D.C., Philadelphia and Atlanta, is
active in major litigations pending in federal and state courts throughout the
United States and has taken a leading role in many important actions on behalf
of defrauded investors, consumers, and companies, as well as victims of human
rights violations. The Coughlin Stoia Web site (http://www.csgrr.com) has more
information about the firm.

Coughlin Stoia Geller Rudman and Robbins LLP
Darren Robbins, 800-449-4900 or 619-231-1058
djr@csgrr.com

Copyright Business Wire 2009